Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tracleer

- PMLiVE

Ipsen announces launch of new UK headquarters in London life sciences community

The Paddington site will serve as one of the company’s three global hubs

- PMLiVE

J&J and Legend’s Carvykti approved by FDA for expanded multiple myeloma use

The cell therapy is the first and only BCMA-targeted therapy to be approved for this condition as early as first relapse

- PMLiVE

Johnson & Johnson to expand cardiovascular capabilities with $13.1bn Shockwave acquisition

Cardiovascular disease results in an estimated 17.9 million global deaths every year

- PMLiVE

Johnson & Johnson’s Opsynvi granted FDA approval in pulmonary arterial hypertension

The rare form of pulmonary hypertension is responsible for up to 1,000 new cases in the US every year

- PMLiVE

J&J and Protagonist’s JNJ-2113 shown to maintain skin clearance in plaque psoriasis

More than 125 million people worldwide are estimated to be living with the immune-mediated skin disorder

- PMLiVE

Johnson & Johnson’s Rybrevant granted FDA approval for lung cancer indications

The drug was previously authorised for use by the US regulator under the accelerated approval pathway

- PMLiVE

Johnson & Johnson’s Tecvayli receives FDA approval for reduced dosing in multiple myeloma patients

More than 35,000 cases of the blood cancer are expected to be diagnosed in the US this year

- PMLiVE

Johnson & Johnson and Protagonist’s JNJ-2113 shows promise in plaque psoriasis

The immune-mediated disease is estimated to affect more than 125 million people worldwide

- PMLiVE

ABPI publishes manifesto for government to accelerate UK life sciences industry

The trade association has called on political parties to commit to three broad goals and requirements

- PMLiVE

Johnson & Johnson’s nipocalimab shows promise in autoimmune disorder studies

The drug is currently being evaluated in patients with gMG and Sjögren’s disease

- PMLiVE

Johnson & Johnson agrees $700m settlement to resolve talcum powder investigations

The deal would resolve US states’ probes into the marketing of its talcum products

- PMLiVE

Johnson & Johnson’s bladder cancer drug Balversa granted full FDA approval

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links